WallStSmart

Insmed Inc (INSM)vsLegend Biotech Corp (LEGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Legend Biotech Corp generates 70% more annual revenue ($1.03B vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -28.8%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

LEGN

Hold

36

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: 0.67

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

LEGN1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
64.2%10/10

Revenue surging 64.2% year-over-year

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

LEGN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-29.1%2/10

ROE of -29.1% — below average capital efficiency

Free Cash FlowQuality
$-126.56M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : LEGN

The strongest argument for LEGN centers on Revenue Growth. Revenue growth of 64.2% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : LEGN

The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while LEGN is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

LEGN is growing revenue faster at 64.2% — sustainability is the question.

LEGN generates stronger free cash flow (-127M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Legend Biotech Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.

Want to dig deeper into these stocks?